Health Care & Life Sciences » Biotechnology | Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC ADR | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
581.20
16,775.70
14,100.00
38,238.60
59,404.40
SG&A Expense
9,610.80
14,423.00
70,016.20
83,133.10
123,884.20
150,886.50
EBIT
9,657.90
14,084.10
55,729.80
72,296.40
91,126.70
99,278.90
Unusual Expense
-
-
-
-
1,044.10
209.60
Non Operating Income/Expense
11.00
270.10
2,770.00
995.10
8,641.70
15,481.80
Interest Expense
6.30
6.50
-
-
-
-
Pretax Income
9,639.10
13,817.30
26,217.50
70,199.00
81,275.20
112,126.10
Income Tax
906.50
1,607.70
3,767.60
885.80
10,385.20
16,773.60
Consolidated Net Income
8,732.60
12,209.60
22,450.00
71,084.80
70,890.00
95,352.50
Net Income
8,732.60
12,209.60
22,450.00
71,084.80
70,890.00
95,352.50
Net Income After Extraordinaries
8,732.60
12,209.60
22,450.00
71,084.80
70,890.00
95,352.50
Net Income Available to Common
8,732.60
12,209.60
22,450.00
71,084.80
70,890.00
95,352.50
EPS (Basic)
-
-
0.27
1.01
0.79
0.98
Basic Shares Outstanding
70,316.60
70,316.60
70,785.30
70,785.70
87,939.50
97,389.80
EPS (Diluted)
0.12
0.17
0.32
1.00
0.81
0.98
Diluted Shares Outstanding
70,316.60
70,316.60
70,785.30
70,785.70
87,939.50
97,389.80
EBITDA
9,610.90
13,841.90
53,240.50
69,033.10
85,645.60
91,482.10
Non-Operating Interest Income
14.10
3.30
26,742.30
1,102.30
2,253.90
2,844.20

About Adaptimmune Therapeutics

View Profile
Address
60 Jubilee Avenue
Abingdon Oxfordshire OX14 4RX
United Kingdom
Employees -
Website http://adaptimmune.com
Updated 07/08/2019
Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.